Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not
{{output}}
Introduction: Body weight can affect exposure, safety and efficacy of antibody-based therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved for wild-type RAS metastatic colorectal cancer, using... ...
